Shared on15 Aug 25
Despite near-term cautious revenue guidance, analysts remain optimistic on OptimizeRx due to Q2 earnings outperformance, improved management transparency, and ongoing strategic initiatives, maintaining the consensus price target at $19.00. Analyst Commentary Bullish analysts highlight OptimizeRx’s Q2 revenues and adjusted EBITDA significantly surpassing forecasts.
Shared on24 Apr 25Fair value Decreased 33%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.